聚乙二醇化成纤维细胞生长因子21类似物Pegozafermin治疗非酒精性脂肪性肝炎的随机对照试验
这项2b期多中心双盲随机对照试验纳入222例经活检证实为非酒精性脂肪性肝炎且纤维化分期为F2或F3的患者,评估Pegozafermin皮下注射的疗效与安全性。结果显示30 mg和44 mg剂量组纤维化改善率显著高于安慰剂组,各剂量组NASH消退率均高于安慰剂组,最常见不良事件为恶心和腹泻。
要点
- 30 mg和44 mg Pegozafermin组纤维化改善率显著高于安慰剂组(差异分别为19和20个百分点)
- Pegozafermin各剂量组NASH消退率均高于安慰剂组,差异为21至35个百分点
- Pegozafermin治疗相关最常见不良事件为恶心和腹泻
核心结论
- 在这项2b期试验中,Pegozafermin治疗带来了纤维化改善,结果支持将Pegozafermin推进至3期研发。
研究设计与样本
- 2b期、多中心、双盲、24周、随机、安慰剂对照试验,纳入经活检证实的非酒精性脂肪性肝炎且纤维化分期为F2或F3的患者。
- 患者随机接受皮下Pegozafermin 15 mg每周一次、30 mg每周一次、44 mg每2周一次,或安慰剂每周一次或每2周一次。
- 222例患者接受随机分组,其中219例接受了Pegozafermin或安慰剂。
主要发现
- 纤维化改善(纤维化分期降低≥1级且NASH无恶化)率:安慰剂汇总组7%,15 mg组22%(与安慰剂差异14个百分点,95%CI -9至38),30 mg组26%(差异19个百分点,95%CI 5至32,P=0.009),44 mg组27%(差异20个百分点,95%CI 5至35,P=0.008)。
- NASH消退且纤维化无恶化率:安慰剂组2%,15 mg组37%(与安慰剂差异35个百分点,95%CI 10至59),30 mg组23%(差异21个百分点,95%CI 9至33),44 mg组26%(差异24个百分点,95%CI 10至37)。
- 与Pegozafermin治疗相关的最常见不良事件为恶心和腹泻。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pegozafermin is a long-acting glycopegylated (pegylated with the use of site-specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia. The efficacy and safety of pegozafermin in patients with biopsy-proven noncirrhotic NASH are not well established. METHODS: In this phase 2b, multicenter, double-blind, 24-week, randomized, placebo-controlled trial, we randomly assigned patients with biopsy-confirmed NASH and stage F2 or F3 (moderate or severe) fibrosis to receive subcutaneous pegozafermin at a dose of 15 mg or 30 mg weekly or 44 mg once every 2 weeks or placebo weekly or every 2 weeks. The two primary end points were an improvement in fibrosis (defined as reduction by ≥1 stage, on a scale from 0 to 4, with higher stages indicating greater severity), with no worsening of NASH, at 24 weeks and NASH resolution without worsening of fibrosis at 24 weeks. Safety was also assessed. RESULTS: Among the 222 patients who underwent randomization, 219 received pegozafermin or placebo. The percentage of patients who met the criteria for fibrosis improvement was 7% in the pooled placebo group, 22% in the 15-mg pegozafermin group (difference vs. placebo, 14 percentage points; 95% confidence interval [CI], -9 to 38), 26% in the 30-mg pegozafermin group (difference, 19 percentage points; 95% CI, 5 to 32; P = 0.009), and 27% in the 44-mg pegozafermin group (difference, 20 percentage points; 95% CI, 5 to 35; P = 0.008). The percentage of patients who met the criteria for NASH resolution was 2% in the placebo group, 37% in the 15-mg pegozafermin group (difference vs. placebo, 35 percentage points; 95% CI, 10 to 59), 23% in the 30-mg pegozafermin group (difference, 21 percentage points; 95% CI, 9 to 33), and 26% in the 44-mg pegozafermin group (difference, 24 percentage points; 95% CI, 10 to 37). The most common adverse events associated with pegozafermin therapy were nausea and diarrhea. CONCLUSIONS: In this phase 2b trial, treatment with pegozafermin led to improvements in fibrosis. These results support the advancement of pegozafermin into phase 3 development. (Funded by 89bio; ENLIVEN ClinicalTrials.gov number, NCT04929483.).
引用
- Loomba R, Sanyal AJ, Kowdley KV, et al. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH. N Engl J Med. 2023. PMID: 37356033. doi:10.1056/NEJMoa2304286
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。